Amylyx Pharmaceuticals, Inc. (AMLX) Financial Statements
$27.20NASDAQ: AMLXMarket Cap $3.41B
Amylyx Pharmaceuticals, Inc. most recently reported annual revenue of $0, a net loss of $145.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Amylyx Pharmaceuticals, Inc.: Revenue fell from $1.0M in 2019 to $0 in 2025, a change of -100.0% over 6 years; net profit was positive in 1 of 7 reported years; operating margin moved from -950.5% to -360.2%, a shift of +590.3 percentage points; the most recent year shows a net loss of $145.0M.
Income Statement — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Revenue
$1.0M
$1.0M
$0
$22.0M
$381.0M
$87.0M
$0
Operating Expenses
$15.0M
$40.0M
$83.0M
$224.0M
$342.0M
$402.0M
$153.0M
Operating Profit
$-14.0M
$-39.0M
$-83.0M
$-201.0M
$39.0M
$-315.0M
$-153.0M
Operating Margin
-950.5%
-6000.8%
0.0%
-905.7%
10.2%
-360.2%
0.0%
Other Income
$0
$-3.0M
$-5.0M
$4.0M
$15.0M
$13.0M
$9.0M
Interest
$1.0M
$2.0M
$0
$0
$0
$0
$0
Depreciation
$14.0M
$0
$0
$0
$1.0M
$1.0M
$1.0M
Profit Before Tax
$-14.0M
$-42.0M
$-88.0M
$-198.0M
$54.0M
$-302.0M
$-145.0M
Tax
$0
$0
$0
$-390,000
$9.3M
$130,000
$-30,000
Net Profit
$-15.0M
$-42.0M
$-88.0M
$-198.0M
$49.0M
$-302.0M
$-145.0M
EPS
$-0.26
$-0.79
$-1.52
$-2.98
$0.70
$-4.43
$-1.53
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$103.0M
$108.0M
$89.0M
$-1.0M
$0
$-1.0M
$0
$0
$0
$0
$0
$0
Operating Expenses
$84.0M
$107.0M
$211.0M
$52.0M
$76.0M
$40.0M
$38.0M
$43.0M
$36.0M
$37.0M
$44.0M
$46.0M
Operating Profit
$19.0M
$2.0M
$-122.0M
$-53.0M
$-76.0M
$-41.0M
$-38.0M
$-43.0M
$-36.0M
$-37.0M
$-44.0M
$-46.0M
Operating Margin
18.2%
1.8%
-137.8%
5223.4%
-18187.7%
6113.4%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$22.0M
$6.0M
$-119.0M
$-73.0M
$-73.0M
$-38.0M
$-36.0M
$-41.0M
$-34.0M
$-33.0M
$-41.0M
$-43.0M
Tax
$6.8M
$26.9M
$-200,000
$0
$0
$1.7M
$0
$0
$0
$-140,000
$0
$0
Net Profit
$21.0M
$5.0M
$-119.0M
$-73.0M
$-73.0M
$-38.0M
$-36.0M
$-41.0M
$-34.0M
$-33.0M
$-41.0M
$-43.0M
EPS
$0.30
$0.07
$-1.75
$-1.07
$-1.07
$-0.55
$-0.42
$-0.46
$-0.37
$-0.28
$-0.37
$-0.39
Over the 7 years reported for Amylyx Pharmaceuticals, Inc., borrowings decreased from $15.0M in 2019 to $6.0M in 2025, cash stood at $227.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.09 times.
Balance Sheet — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Total Assets
$3.0M
$14.0M
$106.0M
$391.0M
$517.0M
$194.0M
$333.0M
Current Assets
$3.0M
$14.0M
$105.0M
$382.0M
$465.0M
$189.0M
$324.0M
Cash
$3.0M
$13.0M
$50.0M
$63.0M
$170.0M
$77.0M
$227.0M
Inventory
$0
$0
$0
$10.0M
$38.0M
$0
$0
Receivables
$0
$0
$0
$15.0M
$40.0M
$0
$0
Fixed Assets
$0
$0
$0
$8.0M
$6.0M
$3.0M
$5.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$46.0M
$284.0M
$201.0M
$99.0M
$90.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$29.0M
$81.0M
$257.0M
$51.0M
$84.0M
$29.0M
$27.0M
Current Liabilities
$5.0M
$7.0M
$17.0M
$47.0M
$82.0M
$28.0M
$23.0M
Borrowings
$15.0M
$1.0M
$0
$6.0M
$4.0M
$2.0M
$6.0M
Other Liabilities
$14.0M
$79.0M
$257.0M
$45.0M
$80.0M
$27.0M
$21.0M
Equity
$0
$0
$0
$0
$0
$0
$0
Reserves
$-25.0M
$-67.0M
$-151.0M
$341.0M
$433.0M
$165.0M
$305.0M
For Amylyx Pharmaceuticals, Inc., operating cash flow was positive in 1 of 7 reported years; free cash flow in the latest year was negative at $123.0M; free cash flow was positive in 1 of 7 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$-11.0M
$-37.0M
$-75.0M
$-180.0M
$12.0M
$-168.0M
$-123.0M
Investing Cash Flow
$0
$0
$-47.0M
$-242.0M
$91.0M
$75.0M
$14.0M
Financing Cash Flow
$0
$0
$-2.0M
$-1.0M
$-3.0M
$-2.0M
$-3.0M
Net Cash Flow
$3.0M
$10.0M
$37.0M
$13.0M
$108.0M
$-92.0M
$149.0M
Free Cash Flow
$-11.0M
$-37.0M
$-75.0M
$-182.0M
$11.0M
$-168.0M
$-123.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.33
EV / EBITDA
-20.34
FCF Yield
-4.10%
Quick Ratio
12.12
Interest Coverage
—
Return 1Y
268.79%
Return 3Y
60.09%
Return 5Y
—
Amylyx Pharmaceuticals, Inc. (AMLX) financials — frequently asked questions
What is Amylyx Pharmaceuticals, Inc.'s annual revenue?
Amylyx Pharmaceuticals, Inc. (AMLX) reported annual revenue of $0 in its most recent fiscal year.
What is Amylyx Pharmaceuticals, Inc.'s net profit?
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $145.0M in its most recent fiscal year.
What is AMLX EV/EBITDA?
Amylyx Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -20.34. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.